Breast cancer patients who have radiotherapy targeted at the original tumour site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return, according to trial results published* in The Lancet today (Wednesday).
The Cancer Research UK-funded IMPORT LOW trial** revealed that five years after treatment, almost all patients were disease free.***
The researchers at 30 radiotherapy centres across the UK, led by The Institute of Cancer Research, London, and the Cancer Research UK Cambridge Centre, studied more than 2,000 women aged 50 or over who had early stage breast cancer that was at a low risk of coming back.
Following breast conserving surgery, some patients were treated with whole breast radiotherapy - the clinical standard - while others received partial breast radiotherapy.****
Women who received partial radiotherapy reported fewer long term changes to the appearance and feel of their breast, than those who had radiotherapy to the whole breast.
Hilary Stobart, 62, from Cambridgeshire, was diagnosed with breast cancer in 2009. She was treated with partial breast radiotherapy as part of the trial. She said: "Any cancer diagnosis is shocking. There's such a lot to take in and it takes time to process.
"I used to be a scientist so I was interested in research and I wanted to know if this trial would be of benefit to me and to patients in the future.
"I was in the group that had the least amount of radiotherapy. I had very few side effects - just some soreness at the start but that was it. I am pleased that I was part of this study."
Following presentation of the initial results, the UK Royal College of Radiologists 2016 breast radiotherapy consensus stated that partial breast radiotherapy could be considered for selected patients using the IMPORT LOW technique. In addition, the Danish Breast Cancer Oncology Group also adopted this partial breast radiotherapy technique for selected patients.
Dr Charlotte Coles, Reader in Breast Radiation Oncology at Cambridge University, chief investigator for the trial and first author of the publication, said: "We started this trial because there was evidence that if someone's cancer returns, it tends to do so close to the site of the original tumour, suggesting that some women receive unnecessary radiation to the whole breast.
"Now we have evidence to support the use of less, but equally effective, radiotherapy for selected patients."
Professor Judith Bliss, scientific lead for the study within the Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, said: "We're delighted that the results of this trial have the potential to lead to a real change in the way selected breast cancer patients are treated.
"The technique used here can be carried out on standard radiotherapy machines so we anticipate that these results will lead to further uptake of this treatment at centres across the country and worldwide."
Professor Arnie Purushotham, Cancer Research UK's senior clinical adviser, said: "One of the challenges when treating early stage breast cancer is trying to minimise the side effects that can have a real impact on a woman's life, without affecting the chances of curing her.
"This approach could spare many women significant physical discomfort and emotional distress."
###
For media enquiries contact Kathryn Ingham in the Cancer Research UK press office on 020 3469 5475 or, out of hours, on 07050 264 059.
Notes to editor:
*Coles, C, E., et al., Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The Lancet.
**IMPORT LOW is a trial looking at ways of improving radiotherapy treatment for low risk early stage breast cancer. The trial recruited 2018 women aged 50 or over, who had breast conserving surgery for invasive ductal adenocarcinoma.
For more information please follow this link http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-comparing-different-ways-of-giving-radiotherapy-for-low-risk-early-stage-breast-cancer
***Around 1 per cent of patients in each of the treatment groups had experienced their cancer returning in the treated breast.
****All three randomly assigned groups received 15 separate treatments over three weeks using a simple form of intensity modulated radiotherapy (IMRT), a technique that delivers an even dose of radiation and reduces long term side effects.
One group received the current standard treatment - full dose radiotherapy to the whole breast.
The second group received full dose radiotherapy to the original tumour site and a lower dose to the rest of the breast (reduced dose radiotherapy).
The third group received full dose radiotherapy to the original tumour site and no additional radiotherapy (partial breast radiotherapy).
About Cancer Research UK
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on vital donations from the public.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.
Journal
The Lancet